Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

LifeLUNG · Improving Life expectancy of LUNG transplant recipients through innovative ex vivo perfusion gene therapy

HORIZONStatus: SIGNED1 November 202531 October 2029EU funding €4,230,837Call HORIZON-MSCA-2024-DN-01

Patient survival after lung transplantation (LTx) for end-stage pulmonary disease is poor (5-year survival rate of 59%) due to ischemia reperfusion injury (IRI) and graft rejection. No therapies are available to prevent IRI, and current immunosuppression causes toxicity and morbidity. Novel strategies are required that can mask the graft from the recipient’s immune systemThe LifeLUNG initiative unites the critical building blocks available in Europe to advance towards a novel paradigm for LTx. Ex vivo lung perfusion (EVLP) is a clinically used platform to maintain active lung physiology outside the body, making pre-LTx organ engineering a reality. The project aims to advancing EVLP technology to enhance our understanding of transplant rejection through accessible models. By utilizing biobanks of lung biopsies from both clinical LTx cases and established animal models of IRI and rejection, LifeLUNG will apply advanced machine learning and AI-driven deep sequencing to identify key immune factors and gene targets. The latter will be targeted in LifeLUNG with gene therapeutic agents (GTAs) that can be delivered during EVLP to selectively modulate immune responses. Several delivery tools including adeno-associated viral vectors, virus-like particles and lipid nanoparticles, will be tailored to ensure precise and graft-specific gene modulation, enhancing the therapeutic potential for reducing IRI and preventing rejection. Also the efficient production strategies of these GTAs will be an integral part of LifeLUNG. In parallel, LifeLUNG will explore the economic and ethical paradigms of genetic modification of lung transplantation and reflect its implementation into the broader research and clinical framework. The interdisciplinary nature of LifeLUNG will support the training of 15 doctoral candidates across clinical, academic, and industrial sectors, fostering collaboration and the development of transferable skills to advance the research objectives.

Consortium · 24 organisations

coordinator

KATHOLIEKE UNIVERSITEIT LEUVEN

BE · €1,057,980

participant

MEDIZINISCHE UNIVERSITAET WIEN

AT · €302,543

participant

MILTENYI BIOTEC BV & CO KG

DE · €290,272

participant

AARHUS UNIVERSITET

DK · €335,890

associatedPartner

Mary Ann Liebert, Inc.

US

participant

LUNDS UNIVERSITET

SE · €324,630

associatedPartner

UNIVERSITAT INTERNACIONAL DE CATALUNYA

ES

associatedPartner

UNIVERSITAT BASEL

CH

associatedPartner

HALO, Patiëntenvereniging longtransplantatie UZ Leuven

BE

participant

OMNISCOPE ESPANA SL

ES · €282,188

associatedPartner

ASTRAZENECA AB

SE

associatedPartner

STICHTING EUROTRANSPLANT INTERNATIONAL FOUNDATION

NL

participant

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

NL · €305,286

participant

ANTLERON

BE · €96,180

associatedPartner

UNIVERSITAT DE BARCELONA

ES

associatedPartner

QbD Group Austria GmbH

AT

participant

ASSOCIATION HOPITAL FOCH

FR · €314,669

participant

FUNDACION HITT

ES · €282,188

associatedPartner

UNIVERSITE PARIS-SACLAY

FR

associatedPartner

UNIVERSITEIT UTRECHT

NL

participant

EBERHARD KARLS UNIVERSITAET TUEBINGEN

DE · €290,272

associatedPartner

INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT

FR

participant

UNIVERSITY COLLEGE LONDON

UK · €348,738

associatedPartner

XVIVO PERFUSION AKTIEBOLAG

SE

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.